Healthcare >> Analyst Interviews >> September 20, 2004


DR. YARON WERBER is senior analyst covering the biotechnology sector at Smith Barney. Mr. Werber joined Smith Barney from SG Cowen Securities were he was a senior analyst and member of the research team that was ranked number one for small and mid-cap coverage by the Greenwich Survey in 2002. In 2003, Dr. Werber was ranked among the top five analysts in the biotech sector by the 'Best on the Street Survey' of the Wall Street Journal. Previously, Dr. Werber was a consultant in the biomedical arena with clients including New England Medical Center, ImClone Systems and EmMax, a pharmaceutical marketing firm, where he worked on projects for Pfizer. Before becoming a consultant, Mr. Werber was Director of Strategic Business Development at NotifyMD, a privately held e-health company. He began his career as a Research Associate and Business Analyst at New England Medical Center, Boston. Dr. Werber received a BS in biology, and a combined MD/MBA from Tufts University. Profile
TWST: Would you begin with a quick overview of your biotech coverage?

Dr. Werber: In my first tranche, I initiated coverage of ImClone Systems

(IMCL), Millennium Pharmaceuticals (MLNM),